{"filing":{"accession_number":"0001827635-26-000028","cik":"0001827635","ticker":"MANE","company_name":"Veradermics, Inc","form":"8-K","filing_date":"2026-08-11","report_date":"2026-08-11","primary_document":"mane-20260811.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000028/mane-20260811.htm"},"events":[{"id":26917,"run_id":24484,"accession_number":"0001827635-26-000028","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Veradermics issued a press release on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $23.5 million, R\u0026D expenses of $18.6 million, G\u0026A expenses of $10.9 million, and cash position of $819.9 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational highlights regarding clinical trial progress for VDPHL01.","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-08-11","form":"8-K","submitted_at":null,"items":[{"id":28216,"accession_number":"0001827635-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Veradermics issued a press release on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $23.5 million, R\u0026D expenses of $18.6 million, G\u0026A expenses of $10.9 million, and cash position of $819.9 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational highlights regarding clinical trial progress for VDPHL01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:16:42.870698+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28216,"accession_number":"0001827635-26-000028","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Veradermics issued a press release on August 11, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $23.5 million, R\u0026D expenses of $18.6 million, G\u0026A expenses of $10.9 million, and cash position of $819.9 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational highlights regarding clinical trial progress for VDPHL01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T12:16:42.870698+00:00","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-08-11"}]}